Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2007;49:941-952
Published online before print March 5, 2007, doi: 10.1161/HYPERTENSIONAHA.107.086900
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
49/5/941    most recent
HYPERTENSIONAHA.107.086900v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pravenec, M.
Right arrow Articles by Kurtz, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pravenec, M.
Right arrow Articles by Kurtz, T. W.
Related Collections
Right arrow Animal models of human disease
Right arrow Functional genomics
Right arrow Hypertension - basic studies
Right arrow Type 2 diabetes
Right arrow Glucose intolerance
Right arrow Genetics of cardiovascular disease

(Hypertension. 2007;49:941.)
© 2007 American Heart Association, Inc.


Novartis Award

Molecular Genetics of Experimental Hypertension and the Metabolic Syndrome

From Gene Pathways to New Therapies

Michal Pravenec; Theodore W. Kurtz

From the Institute of Physiology and Center for Applied Genomics (M.P.), Czech Academy of Sciences, Prague, Czech Republic; and the Department of Laboratory Medicine (T.W.K.), University of California San Francisco.

Correspondence to Theodore W. Kurtz, University of California San Francisco Clinical Laboratories, 185 Berry St, Suite 290, San Francisco, CA 94107. E-mail KurtzT{at}Labmed2.ucsf.edu

Genetic studies of human and experimental hypertension provide a means to identify key pathways that predispose individuals to increased blood pressure and associated risk factors for cardiovascular and metabolic diseases. The pathways so identified can then serve as targets for therapeutic intervention. This article discusses genetic studies in animal models of hypertension in which specific genes have been identified that regulate blood pressure and biochemical features of the metabolic syndrome. Consistent with studies in humans with monogenic disorders of blood pressure regulation, studies in rat models have demonstrated that naturally occurring genetic variation in pathways regulating sodium chloride transport can contribute to inherited variation in blood pressure. Such studies have also indicated that naturally occurring variation in genes, such as Cd36, that regulate fatty acid metabolism and ectopic accumulation of fat and fat metabolites can influence both biochemical and hemodynamic features of the metabolic syndrome and mediate the antidiabetic effects of drugs that activate the peroxisome proliferator-activated receptor-{gamma}. Angiotensin II receptor blockers with the ability to selectively modulate activity of peroxisome proliferator-activated receptor-{gamma} and expression of genes in these fat metabolism pathways may represent useful prototypes for a new class of transcription modulating drugs aimed at treating patients with hypertension and the metabolic syndrome.


Key Words: genetics • rats • inbred SHR • metabolic syndrome X • hypertension • angiotensin II type 1 receptor blockers • peroxisome proliferator-activated receptors




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
X. Jin, T. S. Ha, and D. P. Smith
SNMP is a signaling component required for pheromone sensitivity in Drosophila
PNAS, August 5, 2008; 105(31): 10996 - 11001.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
L. Love-Gregory, R. Sherva, L. Sun, J. Wasson, T. Schappe, A. Doria, D.C. Rao, S. C. Hunt, S. Klein, R. J. Neuman, et al.
Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol
Hum. Mol. Genet., June 1, 2008; 17(11): 1695 - 1704.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Pravenec, L. Kazdova, V. Landa, V. Zidek, P. Mlejnek, M. Simakova, P. Jansa, J. Forejt, V. Kren, D. Krenova, et al.
Identification of Mutated Srebf1 as a QTL Influencing Risk for Hepatic Steatosis in the Spontaneously Hypertensive Rat
Hypertension, January 1, 2008; 51(1): 148 - 153.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
N. H. Lee, B. J. Haas, N. E. Letwin, B. C. Frank, T. V. Luu, Q. Sun, C. D. House, S. Yerga-Woolwine, P. Farms, E. Manickavasagam, et al.
Cross-Talk of Expression Quantitative Trait Loci Within 2 Interacting Blood Pressure Quantitative Trait Loci
Hypertension, December 1, 2007; 50(6): 1126 - 1133.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Saad, S. Yerga-Woolwine, J. Saikumar, P. Farms, E. Manickavasagam, E. J. Toland, and B. Joe
Congenic Interval Mapping of RNO10 Reveals a Complex Cluster of Closely-Linked Genetic Determinants of Blood Pressure
Hypertension, November 1, 2007; 50(5): 891 - 898.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Cardiovascular DiseaseHome page
S. Sookoian and C. J. Pirola
Review: Genetics of the cardiometabolic syndrome: new insights and therapeutic implications
Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 37 - 47.
[Abstract] [PDF]


Home page
HypertensionHome page
H. Hitomi, H. Kiyomoto, A. Nishiyama, T. Hara, K. Moriwaki, K. Kaifu, G. Ihara, Y. Fujita, T. Ugawa, and M. Kohno
Aldosterone Suppresses Insulin Signaling Via the Downregulation of Insulin Receptor Substrate-1 in Vascular Smooth Muscle Cells
Hypertension, October 1, 2007; 50(4): 750 - 755.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. F. Lien, A. J. Brown, J. D. Ard, C. Loria, T. P. Erlinger, A. C. Feldstein, P.-H. Lin, C. M. Champagne, A. C. King, H. L. McGuire, et al.
Effects of PREMIER Lifestyle Modifications on Participants With and Without the Metabolic Syndrome
Hypertension, October 1, 2007; 50(4): 609 - 616.
[Abstract] [Full Text] [PDF]